GlassScriptPhysician profile
David A Welch
NPI 1285602649
$6,201.32
in general payments reported to CMS, 2019-2025
30 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 91% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,345 · 2022: $62.03 · 2023: $2,302 · 2024: $1,318 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,294 · Travel and Lodging: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,294.32 |
| Travel and Lodging | $1,499.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $1,475.88 | 2023 | Intracept |
| Boston Scientific Corporation | $1,090.76 | 2024-2025 | Intracept, Patient Trial Kit, Intracept Rf Probe |
| Abbvie INC. | $1,023.12 | 2021-2025 | |
| Abbott Laboratories | $661.22 | 2023-2025 | Eterna, Proclaim |
| Amgen INC. | $291.06 | 2021-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $288.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $160.69 | 2021-2025 | Ajovy |
| Collegium Pharmaceutical, INC. | $137.41 | 2021-2025 | Xtampza, Belbuca |
| Vertex Pharmaceuticals Incorporated | $134.19 | 2025 | |
| Forte Bio-Pharma LLC | $113.28 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $107.01 | 2021-2023 | Ztlido |
| Averitas Pharma INC. | $86.93 | 2023-2025 | Qutenza |
| Lundbeck LLC | $86.02 | 2021-2023 | Vyepti |
| Lilly USA, LLC | $73.91 | 2021 | |
| Alexion Pharmaceuticals, INC. | $72.82 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.27 | 2021 | |
| Biodelivery Sciences International, INC. | $50.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.81 | 2021 | |
| Si-Bone, INC. | $42.19 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $38.58 | 2024 | Horizant |
| Allergan, INC. | $25.16 | 2021 | |
| Merz Pharmaceuticals, LLC | $24.80 | 2024 | Xeomin |
| Avanos Medical | $22.73 | 2025 | Genvisc 850 Sodium Hyaluronate |
| Pacira Pharmaceuticals Incorporated | $18.90 | 2023 | Zilretta, Iovera, Exparel |
| Medtronic, INC. | $14.90 | 2024 | Synchromedii |
| Idorsia Pharmaceuticals US INC | $13.23 | 2023 | Quviviq |
| Antares Pharma, INC. | $12.72 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.34 | 2021 | |
| Ibsa Pharma INC. | $12.14 | 2021 | |
| Grt US Holding, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.